Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
In late January 2026, Palomar executives sold hundreds of thousands in shares despite strong earnings and rising stock.
In late January 2026, multiple Palomar (PLMR) executives, including the CEO, CFO, president, COO, and other insiders, sold shares totaling hundreds of thousands of dollars in proceeds.
The transactions, disclosed in SEC filings, reduced their stakes by low-single-digit percentages.
Despite the insider selling, Palomar reported strong Q4 earnings on November 6, 2025, with $2.01 EPS and $244.66 million in revenue, surpassing estimates.
The stock closed at $124.22 on February 3, up $0.63, with trading volume above average.
Analysts maintain a "Moderate Buy" consensus rating with a $159.50 target, and several firms upgraded the stock in early 2026.
The company, a specialty insurance holding firm focused on medical stop-loss and program management, has a $3.29 billion market cap and 90.25% institutional ownership.
A finales de enero de 2026, los ejecutivos de Palomar vendieron cientos de miles de acciones a pesar de las fuertes ganancias y el aumento del stock.